Vical

defunct

About

Defunct Company

Areas of Focus

Categories

MergedBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (20)

Total Trials

20

As Lead Sponsor

13

As Collaborator

7

Total Enrollment

1,574

By Phase

PHASE2: 7PHASE1: 8PHASE1/PHASE2: 2PHASE3: 3

By Status

COMPLETED: 16TERMINATED: 3WITHDRAWN: 1

Clinical Trials Pipeline19 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Today

Hover over trial bars to see details

Recent Trials

NCT03327727Lead Sponsor

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

PHASE2Terminated

Started: Feb 20, 2018 · Completed: Jan 14, 2019

NCT02837575Lead Sponsor

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

PHASE2Completed

261 participants

Started: Sep 30, 2016 · Completed: Dec 31, 2018

NCT02594566Collaborator

Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine

PHASE1Withdrawn

Started: Nov 30, 2015 · Completed: Feb 28, 2017

NCT02030301Lead Sponsor

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

PHASE1/PHASE2Completed

165 participants

Started: Dec 31, 2013 · Completed: Feb 29, 2016

NCT02103426Collaborator

An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients

PHASE1Completed

48 participants

Started: Dec 30, 2013 · Completed: May 10, 2016

View all 20 trials →

Funding History (20)

8-K

Mar 7, 2024

8-K

Feb 16, 2024

DEFA14A

Feb 14, 2024

DEF 14A

Jan 17, 2024

DEFA14A

Jan 17, 2024

8-K

Jan 3, 2024

DEFA14A

Dec 27, 2023

8-K

Dec 27, 2023

DEFA14A

Dec 19, 2023

S-1/A

Dec 19, 2023

Related Companies

Brickell Biotech

merged